Au contraire in this case; Shkreli, wearing a black T-shirt and dark jeans, had pulled up a spreadsheet that he said listed every single rare disease in existence, its treatment or lack thereof, and the complexity involved in designing a drug to attack it. He said that Turing will spend some 60 to 70 percent of its revenues on research, in contrast to the 15 percent or so spent by big pharmaceutical companies (and the 3 percent spent by Valeant). I asked Eliseo Salinas, the company’s president of research and development, who had previously worked in the same job at the well-known drug company Shire before joining Turing, if Shkreli knew what he was doing. “I’ve been reporting to C.E.O.’s for the last 11 years,†he said. “I’ve had a good relationship with all of them, but with Martin, I don’t have to explain anything. He just picks it up.†He added, “People obsess about Martin and his persona, but what I see is a very young entrepreneur who wants to be successful through primary research, not through commercial manipulation. He is putting his money where his words are.â€
60-70% goes into research...all he has to do is default on that for that to be obvious. Turing has to file with the SEC . The data will need to be there. ( of course, if he is cooking the books, you will see whatever he wants you to see) The point, if you read that entire article is quite apparent....lol...
At first glance with the bullshit and the smoke screen( boohoo single mommy with AIDS), kicked up by BigP and anyone with a grudge over whatever, what he is doing is lost because that is the point of the legal smoke screen.
Daraprim is not 'safe' it causes a lot of nasty side effects....check the research MissC...Shkreli found a unique niche to exploit...it's a win/win if Turing can improve on the drug and a win for him regardless. That is what business is about...making money. He is no more or less guilty than the rest of BigP.
Shkreli is a diamond in the rough that that has been sprayed with the odiousness of BigP's bullshit...lol...and he knows it.